Glucocorticoid efficacy and treatment strategies for drug-induced liver injury: a literature review.

Humans Glucocorticoids / adverse effects Chemical and Drug Induced Liver Injury / etiology Treatment Outcome Anti-Inflammatory Agents / therapeutic use
Chronic drug-induced liver injury Drug-induced acute liver failure Drug-induced autoimmune-like hepatitis Drug-induced liver injury Drug-induced vanishing bile duct syndrome Glucocorticoids Treatment strategies

Journal

Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234

Informations de publication

Date de publication:
31 Jul 2024
Historique:
received: 13 06 2024
accepted: 18 07 2024
medline: 31 7 2024
pubmed: 31 7 2024
entrez: 31 7 2024
Statut: epublish

Résumé

Drug-induced liver injury (DILI) is an adverse reaction to drugs and their metabolites. The activation of adaptive immune and inflammatory responses plays an important role in the pathogenesis of DILI. Glucocorticoids (GCs) have powerful anti-inflammatory and immunosuppressive effects and have been used to treat a variety of immune-mediated liver diseases. Due to the important role of the immune system in DILI, GCs are widely used in the clinical treatment of DILI; however, whether they are beneficial to patients remains controversial. There is no uniform standard for the timing, dosage, and population selection of GCs, which mainly depend on the clinician's experience. Therefore, elucidating whether GCs are beneficial for patients with DILI is an urgent clinical problem. Our review summarizes the recent literature and discusses the clinical efficacy, applicable population, application timing, and efficacy of GCs in special types of DILI, providing a reference for the clinical application of GCs.

Identifiants

DOI: 10.1007/s11033-024-09806-w PMID: 39083110
pubmed: 39083110
doi: 10.1007/s11033-024-09806-w
pii: 10.1007/s11033-024-09806-w
doi:

Substances chimiques

Glucocorticoids 0
Anti-Inflammatory Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

879

Subventions

Organisme : National Natural Science Foundation of China
ID : No. 82270551
Organisme : National Natural Science Foundation of China
ID : No. 82270551
Organisme : National Natural Science Foundation of China
ID : No. 82270551
Organisme : National Natural Science Foundation of China
ID : No. 82270551
Organisme : National Natural Science Foundation of China
ID : No. 82270551
Organisme : National Natural Science Foundation of China
ID : No. 82270551
Organisme : National Natural Science Foundation of China
ID : No. 82270551
Organisme : National Natural Science Foundation of China
ID : No. 82270551
Organisme : Key Research and Development Projects of Shaanxi Province
ID : No. 2022ZDLSF03-03
Organisme : Key Research and Development Projects of Shaanxi Province
ID : No. 2022ZDLSF03-03
Organisme : Key Research and Development Projects of Shaanxi Province
ID : No. 2022ZDLSF03-03
Organisme : Key Research and Development Projects of Shaanxi Province
ID : No. 2022ZDLSF03-03
Organisme : Key Research and Development Projects of Shaanxi Province
ID : No. 2022ZDLSF03-03
Organisme : Key Research and Development Projects of Shaanxi Province
ID : No. 2022ZDLSF03-03
Organisme : Key Research and Development Projects of Shaanxi Province
ID : No. 2022ZDLSF03-03
Organisme : Key Research and Development Projects of Shaanxi Province
ID : No. 2022ZDLSF03-03

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Nature B.V.

Références

Andrade RJ, Chalasani N, Björnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, Devarbhavi H, Merz M, Lucena MI, Kaplowitz N, Aithal GP (2019) Drug-induced liver injury. Nat Reviews Disease Primers 5. https://doi.org/10.1038/s41572-019-0105-0
Bjornsson ES (2021) Clinical management of patients with drug-induced liver injury (DILI). United Eur Gastroenterol J 9:781–786. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0
Licata A (2016) Adverse drug reactions and organ damage: the liver. Eur J Intern Med 28:9–16. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 26827101
Li X, Tang J, Mao Y (2022) Incidence and risk factors of drug-induced liver injury. Liver Int 42:1999–2014. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 35353431
Saithanyamurthi H, Faust AJ (2017) Drug-Induced Liver Disease. Clin Liver Dis 21:21–34. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 27842773
Hermann RP, Rockey DC, Suzuki A, Merz M, Tillmann HL (2022) A novel phenotype-based drug‐induced liver injury causality assessment tool (DILI‐CAT) allows for signal confirmation in early drug development. Aliment Pharmacol Ther 55:1028–1037. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 35266155 pmcid: 9164935
Devarbhavi H, Aithal G, Treeprasertsuk S, Takikawa H, Mao Y, Shasthry SM, Hamid S, Tan SS, Philips CA, George J et al (2021) Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. Hep Intl 15:258–282. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0
Li M, Luo Q, Tao Y, Sun X, Liu C (2022) Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review. Front Pharmacol 12. https://doi.org/10.1038/s41572-019-0105-0
Hassan A, Fontana RJ (2018) The diagnosis and management of idiosyncratic drug-induced liver injury. Liver Int 39:31–41. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 30003672
Björnsson HK, Björnsson ES (2022) Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management. Eur J Intern Med 97:26–31. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 34772600
Allison R, Guraka A, Shawa IT, Tripathi G, Moritz W, Kermanizadeh A (2023) Drug induced liver injury – a 2023 update. J Toxicol Environ Health Part B 26:442–467. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0
Yan M, Huo Y, Yin S, Hu H (2018) Mechanisms of acetaminophen-induced liver injury and its implications for therapeutic interventions. Redox Biol 17:274–283. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 29753208 pmcid: 6006912
Fontana RJ, Liou I, Reuben A, Suzuki A, Fiel MI, Lee W, Navarro V (2023) AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury. Hepatology 77:1036–1065. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 35899384
Yu Y-c, Mao Y-m, Chen C-w, Chen J-j, Chen J, Cong W-m, Ding Y, Duan Z et al (2017) -p, Fu Q-c, Guo X-y, CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatology International, 11:221–241. https://doi.org/10.1038/s41572-019-0105-0
Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, Watkins PB, Navarro V, Barnhart H et al (2015) Features and outcomes of 899 patients with Drug-Induced Liver Injury: the DILIN prospective study. Gastroenterology 148:1340–1352e1347. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 25754159
Timmermans S, Souffriau J, Libert C (2019) A General introduction to Glucocorticoid Biology. Front Immunol. 10 https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 31481961 pmcid: 6710339
Lesesne HR, Fallon HJ (1973) Treatment of Liver Disease with corticosteroids. Med Clin North Am 57:1191–1201. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 4593197
Tujios S, Stravitz RT, Lee WM (2022) Management of Acute Liver failure: Update 2022. Semin Liver Dis 42:362–378. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 36001996 pmcid: 10576953
Xue R, Meng Q (2019) The management of glucocorticoid therapy in liver failure. Front Immunol. 10 https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 31969881 pmcid: 6901946
Ye C, Li W, Li L, Zhang K (2022) Glucocorticoid treatment strategies in liver failure. Front Immunol. 13 https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 36761162 pmcid: 9795844
Komori A (2021) Recent updates on the management of autoimmune hepatitis. Clin Mol Hepatol 27:58–69. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 33291862
Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH (2018) ACG Clinical Guideline: alcoholic liver disease. Am J Gastroenterol 113:175–194. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 29336434 pmcid: 6524956
Mosedale M, Watkins PB (2017) Drug-induced liver injury: advances in mechanistic understanding that will inform risk management. Clin Pharmacol Ther 101:469–480. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 27861792
Pu S, Pan Y, Zhang Q, You T, Yue T, Zhang Y, Wang M (2023) Endoplasmic reticulum stress and mitochondrial stress in Drug-Induced Liver Injury. Molecules 28. https://doi.org/10.1038/s41572-019-0105-0
Villanueva-Paz M, Morán L, López-Alcántara N, Freixo C, Andrade RJ, Lucena MI, Cubero FJ (2021) Oxidative stress in Drug-Induced Liver Injury (DILI): from mechanisms to biomarkers for Use in Clinical Practice. Antioxidants, p 10. https://doi.org/10.1038/s41572-019-0105-0
Ortega-Alonso A, Stephens C, Lucena M, Andrade R (2016) Case characterization, clinical features and risk factors in Drug-Induced Liver Injury. Int J Mol Sci 17. https://doi.org/10.1038/s41572-019-0105-0
Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, Aithal GP (2017) Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 66:1154–1164. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 28341748
Urban TJ, Nicoletti P, Chalasani N, Serrano J, Stolz A, Daly AK, Aithal GP, Dillon J, Navarro V, Odin J et al (2017) Minocycline hepatotoxicity: clinical characterization and identification of HLA-B∗35:02 as a risk factor. J Hepatol 67:137–144. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 28323125 pmcid: 5634615
Cruz-Topete D, Cidlowski JA (2015) One hormone, two actions: anti- and pro-inflammatory effects of glucocorticoids. Neuroimmunomodulation 22:20–32. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 25227506
Syed AP, Greulich F, Ansari SA, Uhlenhaut NH (2020) Anti-inflammatory glucocorticoid action: genomic insights and emerging concepts. Curr Opin Pharmacol 53:35–44. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 32416533
Teschke R, Biomedicines (2022) 11. https://doi.org/10.1038/s41572-019-0105-0
Wuillemin N, Terracciano L, Beltraminelli H, Schlapbach C, Fontana S, Krähenbühl S, Pichler WJ, Yerly D (2014) T cells infiltrate the liver and kill hepatocytes in HLA-B∗57:01-Associated Floxacillin-Induced Liver Injury. Am J Pathol 184:1677–1682. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 24731753
Cain DW, Cidlowski JA (2017) Immune regulation by glucocorticoids. Nat Rev Immunol 17:233–247. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 28192415 pmcid: 9761406
Fontana RJ, Bjornsson ES, Reddy R, Andrade RJ (2023) The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury. Clin Gastroenterol Hepatol 21:2088–2099. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 36868489
Björnsson ES, Vucic V, Stirnimann G, Robles-Díaz M (2022) Role of corticosteroids in Drug-Induced Liver Injury. Syst Rev Front Pharmacol 13. https://doi.org/10.1038/s41572-019-0105-0
Wree A, Dechêne A, Herzer K, Hilgard P, Syn W-K, Gerken G, Canbay A (2011) Steroid and ursodesoxycholic acid combination therapy in severe Drug-Induced Liver Injury. Digestion 84:54–59. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 21304237
Borlak J, van Bömmel F, Berg T (2017) N-acetylcysteine and prednisolone treatment improved serum biochemistries in suspected flupirtine cases of severe idiosyncratic liver injury. Liver Int 38:365–376. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 28782153
Fontana RJ, Kleiner DE, Chalasani N, Bonkovsky H, Gu J, Barnhart H, Li Y-J, Hoofnagle JH (2023) The impact of patient age and corticosteroids in patients with Sulfonamide Hepatotoxicity. Am J Gastroenterol 118:1566–1575. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 36848311
Niu H, Ma J, Medina-Caliz I, Robles‐Diaz M, Bonilla‐Toyos E, Ghabril M, Lucena MI, Alvarez‐Alvarez I, Andrade RJ (2022) Potential benefit and lack of serious risk from corticosteroids in drug‐induced liver injury: an international, multicentre, propensity score‐matched analysis. Aliment Pharmacol Ther 57:886–896. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 36547393
Wan Y-M, Wu J-F, Li Y-H, Wu H-M, Wu X-N, Xu Y (2019) Prednisone is not beneficial for the treatment of severe drug-induced liver injury. Medicine 98. https://doi.org/10.1038/s41572-019-0105-0
Pang L, Yang W, Hou F (2018) Features and outcomes from a retrospective study of 570 hospitalized Chinese patients with drug-induced liver injury. Clin Res Hepatol Gastroenterol 42:48–56. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 28927656
Kakisaka K, Suzuki Y, Takikawa Y (2020) Disease severity of acute liver injury caused by drug-induced liver injury may affect the response to corticosteroid therapy. Liver Int 40:1781–1781. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 31883191
Wang X, Xu H-r, Wang Y-d, Shen C, Zhao C-y (2020) Liver failure and glucocorticoid resistance. Chin J Hepatol 28:888–892. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0
Parlati L, Marcin K, Terris B, Vallet-Pichard A, Corouge M, Hollande C, Sogni P, Mallet V, Pol S (2023) Histological characteristics and management of Hepatitis on Immune Checkpoint inhibitors: a Retrospective descriptive study. J Clin Med 12. https://doi.org/10.1038/s41572-019-0105-0
Andrade RJ, Robles-Díaz M (2019) Diagnostic and prognostic assessment of suspected drug‐induced liver injury in clinical practice. Liver Int 40:6–17. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 31578817
Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, Hayashi PH, Davern TJ, Navarro V, Reddy R et al (2013) Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 59:661–670. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 24037963
Lucena MI, Sanabria J, García-Cortes M, Stephens C, Andrade RJ (2020) Drug-induced liver injury in older people. Lancet Gastroenterol Hepatol 5:862–874. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 32818465
Shingina A, Mukhtar N, Wakim-Fleming J, Alqahtani S, Wong RJ, Limketkai BN, Larson AM, Grant L (2023) Acute Liver failure guidelines. Am J Gastroenterol 118:1128–1153. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 37377263
Hu PF, Xie WF (2019) Corticosteroid therapy in drug-induced liver injury: pros and cons. J Dig Dis 20:122–126. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 30582289
Hu PF, Wang PQ, Chen H, Hu XF, Xie QP, Shi J, Lin L, Xie WF (2016) Beneficial effect of corticosteroids for patients with severe drug-induced liver injury. J Dig Dis 17:618–627. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 27426618
Mao Y, Ma S, Liu C, Liu X, Su M, Li D, Li Y, Chen G, Chen J, Chen J et al (2024) Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update. Hep Intl. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0
Asif BA, Koh C, Phillips EJ, Gu J, Li Y-J, Barnhart H, Chalasani N, Fontana RJ, Hayashi PH, Navarro VJ, Hoofnagle JH (2024) Vancomycin-Induced Liver Injury, DRESS, and HLA-A∗32:01. J Allergy Clin Immunology: Pract 12:168–174e162. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0
Vuppalanchi R, Ghabril M (2022) Review article: clinical assessment of suspected drug-induced liver injury and its management. Aliment Pharmacol Ther 56:1516–1531. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 36282208
Bessone F, Bjornsson ES (2022) Checkpoint inhibitor-induced hepatotoxicity: role of liver biopsy and management approach. World J Hepatol 14:1269–1276. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 36158917 pmcid: 9376772
Sheth R, Gudd CLC, Thursz MR, Triantafyllou E, Possamai LA (2023) Immune Checkpoint inhibitor-Induced Liver Injury. Semin Liver Dis 43:402–417. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 38101418
Karkhanis J, Verna EC, Chang MS, Stravitz RT, Schilsky M, Lee WM, Brown RS (2014) Steroid use in acute liver failure. Hepatology 59:612–621. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 23929808
Kakisaka K, Kataoka K, Suzuki Y, Kuroda H, Takikawa Y (2017) Appropriate timing to start and optimal response evaluation of high-dose corticosteroid therapy for patients with acute liver failure. J Gastroenterol 52:977–985. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 28078470
Hoofnagle JH, Longo DL, Björnsson ES (2019) Drug-Induced Liver Injury — types and phenotypes. N Engl J Med 381:264–273. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 31314970
Stine JG, Lewis JH (2015) Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol 10:517–536. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 26633044 pmcid: 5074808
Björnsson ES (2020) Epidemiology, predisposing factors, and outcomes of Drug-Induced Liver Injury. Clin Liver Dis 24:1–10. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 31753242
Wendon J, Cordoba J, Dhawan A, Larsen FS, Manns M, Nevens F, Samuel D, Simpson KJ, Yaron I, Bernardi M (2017) EASL Clinical practical guidelines on the management of acute (fulminant) liver failure. J Hepatol 66:1047–1081. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 28417882
Tujios SR, Lee WM (2017) Acute liver failure induced by idiosyncratic reaction to drugs: challenges in diagnosis and therapy. Liver Int 38:6–14. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 28771932 pmcid: 5741491
Andrade RJ, Aithal GP, Björnsson ES, Kaplowitz N, Kullak-Ublick GA, Larrey D, Karlsen TH (2019) EASL Clinical Practice guidelines: drug-induced liver injury. J Hepatol 70:1222–1261. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0
Chayanupatkul M, Schiano TD (2020) Acute Liver failure secondary to Drug-Induced Liver Injury. Clin Liver Dis 24:75–87. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 31753252
García-Cortés M, Ortega-Alonso A, Andrade RJ (2021) Safety of treating acute liver injury and failure. Exp Opin Drug Saf 21:191–203. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0
Miah A, Tinoco G, Zhao S, Wei L, Johns A, Patel S, Li M, Grogan M, Lopez G, Husain M et al (2022) Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival. J Cancer Res Clin Oncol 149:2235–2242. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 36070148 pmcid: 10191203
Nishida N, Kudo M (2019) Liver damage related to immune checkpoint inhibitors. Hep Intl 13:248–252. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0
Remash D, Prince DS, McKenzie C, Strasser SI, Kao S, Liu K (2021) Immune checkpoint inhibitor-related hepatotoxicity: a review. World J Gastroenterol 27:5376–5391. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 34539139 pmcid: 8409159
Matsubara T, Nishida T, Higaki Y, Tomita R, Shimakoshi H, Shimoda A, Osugi N, Sugimoto A, Takahashi K, Nakamatsu D et al (2018) Nivolumab induces sustained Liver Injury in a patient with malignant melanoma. Intern Med 57:1789–1792. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 29434164 pmcid: 6047996
Huffman BM, Kottschade LA, Kamath PS, Markovic SN (2018) Hepatotoxicity after Immune checkpoint inhibitor therapy in Melanoma. Am J Clin Oncol 41:760–765. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 28749795
Riveiro-Barciela M, Barreira‐Díaz A, Salcedo MT, Callejo‐Pérez A, Muñoz‐Couselo E, Iranzo P, Ortiz‐Velez C, Cedrés S, Díaz‐Mejía N, Ruiz‐Cobo JC et al (2024) An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor‐induced liver injury. Aliment Pharmacol Ther 59:865–876. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 38327102
Clinton JW, Kiparizoska S, Aggarwal S, Woo S, Davis W, Lewis JH (2021) Drug-Induced Liver Injury: highlights and controversies in the recent literature. Drug Saf 44:1125–1149. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 34533782 pmcid: 8447115
Gauci M-L, Baroudjian B, Bédérède U, Zeboulon C, Delyon J, Allayous C, Madelaine I, Eftekhari P, Resche-Rigon M, Poté N et al (2021) Severe immune-related hepatitis induced by immune checkpoint inhibitors: clinical features and management proposal. Clin Res Hepatol Gastroenterol 45. https://doi.org/10.1038/s41572-019-0105-0
De Martin E, Michot J-M, Papouin B, Champiat S, Mateus C, Lambotte O, Roche B, Antonini TM, Coilly A, Laghouati S et al (2018) Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 68:1181–1190. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 29427729
Meyerson C, Naini BV (2020) Something old, something new: liver injury associated with total parenteral nutrition therapy and immune checkpoint inhibitors. Hum Pathol 96:39–47. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 31669893
Cunningham M, Gupta R, Butler M (2024) Checkpoint inhibitor hepatotoxicity: pathogenesis and management. Hepatology 79:198–212. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 36633259
Miller ED, Abu-Sbeih H, Styskel B, Nogueras Gonzalez GM, Blechacz B, Naing A, Chalasani N (2020) Clinical characteristics and adverse impact of Hepatotoxicity due to Immune Checkpoint inhibitors. Am J Gastroenterol 115:251–261. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 31789632
Zhang N, Li Z, Liu Y, Shi X, Shi D, Li Y, Si X, Xun Z, Shao J, Zhao H, Wang H (2024) Management and treatment of severe immune-related hepatotoxicity based on clinical and pathological characteristics. Hep Intl. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0
Li M, Wong D, Vogel AS, Sack JS, Rahma OE, Hodi FS, Zucker SD, Grover S (2022) Effect of corticosteroid dosing on outcomes in high-­grade immune checkpoint inhibitor hepatitis Hepatology. 75:531–540. https://doi.org/10.1038/s41572-019-0105-0
Regev A, Avigan MI, Kiazand A, Vierling JM, Lewis JH, Omokaro SO, Di Bisceglie AM, Fontana RJ, Bonkovsky HL, Freston JW et al (2020) Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. J Autoimmun 114. https://doi.org/10.1038/s41572-019-0105-0
Ito T, Ishigami M, Yamamoto T, Mizuno K, Yamamoto K, Imai N, Ishizu Y, Honda T, Kawashima H, Yasuda S et al (2021) Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies. Hep Intl 15:1278–1287. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0
Ueno M, Takabatake H, Hata A, Kayahara T, Morimoto Y, Notohara K, Mizuno M (2022) Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: a report of two cases and literature review. Cancer Rep 5. https://doi.org/10.1038/s41572-019-0105-0
Ziemer M, Koukoulioti E, Beyer S, Simon JC, Berg T (2017) Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. J Hepatol 66:657–659. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 27908801
Andrade RJ, Aithal GP, de Boer YS, Liberal R, Gerbes A, Regev A, Terziroli Beretta-Piccoli B, Schramm C, Kleiner DE, De Martin E et al (2023) Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): an expert opinion meeting report. J Hepatol 79:853–866. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 37164270 pmcid: 10735171
Chung Y, Morrison M, Zen Y, Heneghan MA (2023) Defining characteristics and long-term prognosis of drug‐induced autoimmune‐like hepatitis: a retrospective cohort study. United Eur Gastroenterol J 12:66–75. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0
García-Cortés M, Ortega‐Alonso A, Matilla‐Cabello G, Medina‐Cáliz I, Castiella A, Conde I, Bonilla‐Toyos E, Pinazo‐Bandera J, Hernández N, Tagle M et al (2023) Clinical presentation, causative drugs and outcome of patients with autoimmune features in two prospective DILI registries. Liver Int 43:1749–1760. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 37269163
Dara L, Ghabril M, Phillips E, Kleiner D, Chalasani N (2024) A 68-Year-old woman with unexplained liver enzyme elevation and active chronic Hepatitis: beware of Drug-Induced Autoimmune-Like Hepatitis. Gastroenterology 166:259–266e251. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 37797776
Chalasani N, Li Y-J, Dellinger A, Navarro V, Bonkovsky H, Fontana RJ, Gu J, Barnhart H, Phillips E, Lammert C et al (2023) Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury. J Hepatol 78:293–300. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 36152763
Licata A, Maida M, Cabibi D, Butera G, Macaluso FS, Alessi N, Caruso C, Craxì A, Almasio PL (2014) Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study. Dig Liver Disease 46:1116–1120. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0
deLemos AS, Foureau DM, Jacobs C, Ahrens W, Russo MW, Bonkovsky HL (2014) Drug-Induced Liver Injury with Autoimmune features. Semin Liver Dis 34:194–204. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 24879983
Björnsson ES, Bergmann O, Jonasson JG, Grondal G, Gudbjornsson B, Olafsson S (2017) Drug-Induced Autoimmune Hepatitis: response to corticosteroids and lack of Relapse after Cessation of steroids. Clin Gastroenterol Hepatol 15:1635–1636. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 28535988
Björnsson HK, Gudbjornsson B, Björnsson ES (2022) Infliximab-induced liver injury: clinical phenotypes, autoimmunity and the role of corticosteroid treatment. J Hepatol 76:86–92. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 34487751
Weber S, Benesic A, Rotter I, Gerbes AL (2019) Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis. Liver Int 39:1906–1917. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 31319011
Weber S, Gerbes AL (2023) Relapse and need for extended immunosuppression: Novel features of Drug-Induced Autoimmune Hepatitis. Digestion 104:243–248. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 36603570
de Boer YS, Kosinski AS, Urban TJ, Zhao Z, Long N, Chalasani N, Kleiner DE, Hoofnagle JH (2017) Features of Autoimmune Hepatitis in patients with drug-induced Liver Injury. Clin Gastroenterol Hepatol 15:103–112e102. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 27311619
Wang Q, Huang A, Wang J-B, Zou Z (2021) Chronic Drug-Induced Liver Injury: Updates and Future challenges. Front Pharmacol 12. https://doi.org/10.1038/s41572-019-0105-0
Bessone F, Robles-Diaz M, Hernandez N, Medina-Caliz I, Lucena MI, Andrade RJ (2019) Assessment of Serious Acute and Chronic Idiosyncratic Drug-Induced Liver Injury in Clinical Practice. Semin Liver Dis 39:381–394. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 31049898
Medina-Caliz I, Robles-Diaz M, Garcia-Muñoz B, Stephens C, Ortega-Alonso A, Garcia-Cortes M, González-Jimenez A, Sanabria-Cabrera JA, Moreno I, Fernandez MC et al (2016) Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. J Hepatol 65:532–542. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 27184533 pmcid: 7458366
Stine JG, Chalasani N (2015) Chronic liver injury induced by drugs: a systematic review. Liver Int 35:2343–2353. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 26346512
Wang JB, Huang A, Wang Y, Ji D, Liang QS, Zhao J, Zhou G, Liu S, Niu M, Sun Y et al (2022) Corticosteroid plus glycyrrhizin therapy for chronic drug- or herb‐induced liver injury achieves biochemical and histological improvements: a randomised open‐label trial. Aliment Pharmacol Ther 55:1297–1310. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 35362188
Huang A, Zhu Y, Liu S-h, Sun Y, Liu Z-r, Liang Q-s, Zhao J, Chang B-x, Bi J-f, Liu J-t et al (2024) An optimized short-­term steroid therapy for chronic drug-­induced liver injury: a prospective randomized clinical trial. Liver Int 44:1–13. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0
Hama N, Abe R, Gibson A, Phillips EJ (2022) Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug reaction with Eosinophilia and systemic symptoms (DRESS): clinical features and Pathogenesis. J Allergy Clin Immunology: Pract 10:1155–1167e1155. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0
Sharifzadeh S, Mohammadpour AH, Tavanaee A, Elyasi S (2020) Antibacterial antibiotic-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review. Eur J Clin Pharmacol 77:275–289. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 33025080 pmcid: 7537982
Medina-Cáliz I, Sanabria-Cabrera J, Villanueva-Paz M, Aukštikalnė L, Stephens C, Robles-Díaz M, Pinazo-Bandera JM, García-Cortes M, Conde I, Soriano G et al (2023) Characterization of drug-induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registries. Arch Toxicol 98:303–325. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 38051367 pmcid: 10761448
Devarbhavi H, Raj S (2018) Drug-induced liver injury with skin reactions: drugs and host risk factors, clinical phenotypes and prognosis. Liver Int 39:802–811. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 30515930
Wei BM, Fox LP, Kaffenberger BH, Korman AM, Micheletti RG, Mostaghimi A, Noe MH, Rosenbach M, Shinkai K, Kwah JH et al (2024) Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management. J Am Acad Dermatol 90:911–926. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 37516356
Devarbhavi H, Kurien SS, Raj S, Patil M, Gowda V, Kothari K, Singh R (2022) Idiosyncratic Drug-Induced Liver Injury Associated with and without drug reaction with Eosinophilia and systemic symptoms. Am J Gastroenterol 117:1709–1713. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 35862835
Zhao Z, Lu M, Ying Y (2024) Case Report: Minocycline-induced drug reaction with eosinophilia and systemic symptoms syndrome: a case report and literature review. Front Pharmacol 15. https://doi.org/10.1038/s41572-019-0105-0
Irabien M, Blanco S, Calderón Á (2021) DRESS syndrome and drug-induced liver injury owing to antituberculous treatment. Gastroenterología Y Hepatología (English Edition) 44:427–428. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0
Miyasaka A, Kumagai I, Masuda T, Takikawa Y (2021) A 51-Year-old woman with Drug-Induced Hypersensitivity Syndrome Associated with Carbamazepine, Reactivation of Human Herpesvirus 6, and Acute Liver failure: a Case Report. Am J Case Rep. 22 https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 34404756 pmcid: 8382023
Mirza S, Hill E, Ludlow SP, Nanjappa S (2017) Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome. Melanoma Res 27:271–273. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 28146044
Huang YS, Wu CY, Chang TT, Peng CY, Lo GH, Hsu CW, Hu CT, Huang YH (2021) Drug-induced liver injury associated with severe cutaneous adverse drug reactions: a nationwide study in Taiwan. Liver Int 41:2671–2680. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 34153177
Brüggen M-C, Walsh S, Ameri MM, Anasiewicz N, Maverakis E, French LE, Ingen-Housz-Oro S, Abe R, Ardern-Jones M, Assier H et al (2024) Management of adult patients with drug reaction with Eosinophilia and systemic symptoms. JAMA Dermatology 160. https://doi.org/10.1038/s41572-019-0105-0
Dobreva I, Karagyozov P (2020) Drug-induced bile Duct Injury - A Short Review. Curr Drug Metab 21:256–259. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 32310045
Bessone F, Hernández N, Tanno M, Roma MG (2021) Drug-Induced vanishing bile Duct Syndrome: from pathogenesis to diagnosis and therapeutics. Semin Liver Dis 41:331–348. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 34130334
Eiswerth MJ, Heckroth MA, Ismail A, Gondim DD, Kaufman R (2022) Infliximab-Induced vanishing bile Duct Syndrome. Cureus. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 35676995 pmcid: 9166458
Maria G, Marco C, MariaI A, Maddalena M, Nicola Z, Francesca C, Pietro I, Paolo B, Diego C (2021) Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature. Immunotherapy 14:175–181. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0
Bonkovsky HL, Kleiner DE, Gu J, Odin JA, Russo MW, Navarro VM, Fontana RJ, Ghabril MS, Barnhart H, Hoofnagle JH (2017) Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology 65:1267–1277. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 27981596
Bak H, Kim H, Lee S, Lee Y, Bang S-M, Lee Y-S (2020) A case of vanishing bile Duct Syndrome after Drug-Induced Liver Injury caused by Pelubiprofen. Yonsei Med J 61. https://doi.org/10.1038/s41572-019-0105-0
Piawah S, Hyland C, Umetsu SE, Esserman LJ, Rugo HS, Chien AJ (2019) A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. npj Breast Cancer. 5 https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 31240240 pmcid: 6570645
Izzo P, Gallo G, Codacci Pisanelli M, D’Onghia G, Macci L, Gabriele R, Polistena A, Izzo L, Izzo S, Basso L (2022) Vanishing bile Duct Syndrome in an adult patient: Case Report and Review of the literature. J Clin Med 11. https://doi.org/10.1038/s41572-019-0105-0
Wasuwanich P, Choudry H, So JM, Lowry S, Karnsakul W (2022) Vanishing bile duct syndrome after drug-induced liver injury. Clin Res Hepatol Gastroenterol 46. https://doi.org/10.1038/s41572-019-0105-0
Shionoya K, Kobayashi M, Kako M, Masuda S, Makazu M, Koizumi K (2024) A case of drug-induced Liver Injury considered steroid-resistant and histologically diagnosed with vanishing bile Duct Syndrome. https://doi.org/10.1038/s41572-019-0105-0 . Internal Medicine
Pofi R, Caratti G, Ray DW, Tomlinson JW (2023) Treating the Side effects of Exogenous glucocorticoids; can we separate the good from the bad? Endocr Rev 44:975–1011. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 37253115 pmcid: 10638606
Kulkarni S, Durham H, Glover L, Ather O, Phillips V, Nemes S, Cousens L, Blomgran P, Ambery P (2022) Metabolic adverse events associated with systemic corticosteroid therapy—a systematic review and meta-analysis. BMJ Open 12. https://doi.org/10.1038/s41572-019-0105-0
Townsend MJ, Benque IJ, Li M, Grover S (2024) Review article: contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors. Aliment Pharmacol Ther 59:1350–1365. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 38590108
Caster O, Conforti A, Viola E, Edwards IR (2014) Methylprednisolone-induced hepatotoxicity: experiences from global adverse drug reaction surveillance. Eur J Clin Pharmacol 70:501–503. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 24384565
Cottin J, Pierre S, Pizzoglio V, Simon C, Durrieu G, Bleyzac N, Gouraud A, Dumortier J (2020) Methylprednisolone-related liver injury: a descriptive study using the French pharmacovigilance database. Clin Res Hepatol Gastroenterol 44:662–673. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 31948782
Zoubek ME, Pinazo-Bandera J, Ortega-Alonso A, Hernández N, Crespo J, Contreras F, Medina-Cáliz I, Sanabria-Cabrera J, Sanjuan-Jiménez R, González-Jiménez A et al (2019) Liver injury after methylprednisolone pulses: a disputable cause of hepatotoxicity. A case series and literature review. United Eur Gastroenterol J 7:825–837. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0
Ueno M, Takabatake H, Kayahara T, Morimoto Y, Notohara K, Mizuno M (2023) Long-term outcomes of drug‐induced autoimmune‐like hepatitis after pulse steroid therapy. Hepatol Res 53:1073–1083. https://doi.org/10.1038/s41572-019-0105-0
doi: 10.1038/s41572-019-0105-0 pubmed: 37347239

Auteurs

Punan Wang (P)

State Key Laboratory of Cancer Biology, National Clinical Research Centre for Digestive Diseases, Xijing Hospital of Digestive Diseases, The Air Force Military Medical University, Xi'an, 710032, Shaanxi, China.

Guanya Guo (G)

State Key Laboratory of Cancer Biology, National Clinical Research Centre for Digestive Diseases, Xijing Hospital of Digestive Diseases, The Air Force Military Medical University, Xi'an, 710032, Shaanxi, China.

Shuangshuang Jiang (S)

State Key Laboratory of Cancer Biology, National Clinical Research Centre for Digestive Diseases, Xijing Hospital of Digestive Diseases, The Air Force Military Medical University, Xi'an, 710032, Shaanxi, China.

Dawei Ding (D)

State Key Laboratory of Cancer Biology, National Clinical Research Centre for Digestive Diseases, Xijing Hospital of Digestive Diseases, The Air Force Military Medical University, Xi'an, 710032, Shaanxi, China.

Jiaqi Yang (J)

State Key Laboratory of Cancer Biology, National Clinical Research Centre for Digestive Diseases, Xijing Hospital of Digestive Diseases, The Air Force Military Medical University, Xi'an, 710032, Shaanxi, China.

Yi Lu (Y)

State Key Laboratory of Cancer Biology, National Clinical Research Centre for Digestive Diseases, Xijing Hospital of Digestive Diseases, The Air Force Military Medical University, Xi'an, 710032, Shaanxi, China.

Ying Han (Y)

State Key Laboratory of Cancer Biology, National Clinical Research Centre for Digestive Diseases, Xijing Hospital of Digestive Diseases, The Air Force Military Medical University, Xi'an, 710032, Shaanxi, China. hanying1@fmmu.edu.cn.

Xinmin Zhou (X)

State Key Laboratory of Cancer Biology, National Clinical Research Centre for Digestive Diseases, Xijing Hospital of Digestive Diseases, The Air Force Military Medical University, Xi'an, 710032, Shaanxi, China. zhouxmm@fmmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Glucocorticoid efficacy and treatment...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hormones, substituts d'hormones et antagonistes d'hormones › Hormones › Glucocorticoïdes › Glucocorticoid efficacy and treatment...
questionsmedicales.fr › Troubles dus à des produits chimiques › Intoxication › Lésions hépatiques dues aux substances › Glucocorticoid efficacy and treatment...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Glucocorticoid efficacy and treatment...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-inflammatoires › Glucocorticoid efficacy and treatment...